Altimmune (NASDAQ:ALT) Posts Earnings Results, Misses Estimates By $0.01 EPS

Altimmune (NASDAQ:ALT) issued its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01), Zacks reports. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 46.96% and a negative net margin of 22,645.37%. During the same period last year, the business earned ($0.32) EPS.

Altimmune Price Performance

NASDAQ ALT traded down $0.16 during midday trading on Friday, hitting $6.17. 2,545,232 shares of the company traded hands, compared to its average volume of 4,437,680. The company has a market cap of $437.47 million, a PE ratio of -3.88 and a beta of 0.13. The company’s 50-day simple moving average is $6.63 and its 200-day simple moving average is $8.07. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.84.

Analysts Set New Price Targets

Several brokerages recently issued reports on ALT. B. Riley reaffirmed a “buy” rating and set a $20.00 target price on shares of Altimmune in a research report on Tuesday, June 25th. Guggenheim lowered Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Tuesday, May 14th. Piper Sandler restated an “overweight” rating and issued a $25.00 target price on shares of Altimmune in a research note on Friday, June 21st. Finally, JMP Securities cut their price objective on Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.80.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.